PMID- 26604823
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151125
LR  - 20200930
IS  - 1179-1349 (Print)
IS  - 1179-1349 (Electronic)
IS  - 1179-1349 (Linking)
VI  - 7
DP  - 2015
TI  - Cross-sectional study on comorbidities and adverse events in patients with 
      advanced and recurrent ovarian cancer in France.
PG  - 431-40
LID - 10.2147/CLEP.S86429 [doi]
AB  - PURPOSE: The purpose of this study was to evaluate the prevalence of 
      comorbidities and adverse events (AEs), and determine the treatment patterns 
      according to platinum-sensitivity status in patients with advanced (stage 
      IIIB-IV) or recurrent epithelial ovarian cancer (EOC). METHODS: A cross-sectional 
      study was carried out in France with patients over 18 years, diagnosed with 
      advanced (stage IIIB-IV) or recurrent EOC between 2009 and 2012. A total of 23 
      physicians (oncologists and gynecologists) participated, contributing 127 
      patients. Data were abstracted by participating physicians into a case report 
      form. RESULTS: Of the 127 patients included, 92 (72.4%) had advanced EOC and 35 
      (27.6%) had recurrent EOC. A total of 73 comorbidities were reported in 44 
      patients (34.6%). Vascular (10.2%), metabolic (7.1%), respiratory (5.5%), and 
      psychiatric disorders (5.5%) were the most common types of comorbidities 
      reported. Prevalence of AEs was 74.8%, of which 12.6% were classified as serious. 
      The most common AEs were anemia (16.5%), hematologic events (12.6%), taste change 
      (11.8%), and headache (7.1%). Throughout the follow-up period, twelve patient 
      deaths were reported (six due to disease progression). Of 35 patients with 
      recurrent disease, 16 were highly platinum sensitive (recurrence >12 months after 
      stopping platinum-based therapy), eleven were partially platinum sensitive 
      (recurrence 6-12 months after stopping platinum-based therapy), seven were 
      platinum resistant (recurrence within 6 months of stopping platinum-based therapy 
      or progression while receiving second- or later-line platinum-based therapy), and 
      one was platinum refractory (recurrence within 6 months from the start of 
      first-line platinum-based therapy). CONCLUSION: In this cross-sectional study of 
      advanced and metastatic ovarian cancer patients, approximately one-third of 
      patients were diagnosed with comorbidities, and approximately three-quarters were 
      diagnosed with AEs (12.6% with severe AEs).
FAU - Le Saux, Olivia
AU  - Le Saux O
AD  - Department of Medical Oncology, Centre Hospitalier Lyon-Sud, Pierre-Benite Cedex, 
      France.
FAU - Taylor, Aliki
AU  - Taylor A
AD  - Center for Observational Research, Amgen Ltd, Uxbridge, UK.
FAU - Chia, Victoria
AU  - Chia V
AD  - Center for Observational Research, Amgen Inc., Thousand Oaks, CA, USA.
FAU - Pillas, Demetris
AU  - Pillas D
AD  - Center for Observational Research, Amgen Ltd, Uxbridge, UK.
FAU - Kaur, Moninder
AU  - Kaur M
AD  - Center for Observational Research, Amgen Ltd, Uxbridge, UK.
FAU - Freyer, Gilles
AU  - Freyer G
AD  - Department of Medical Oncology, Centre Hospitalier Lyon-Sud, Pierre-Benite Cedex, 
      France.
LA  - eng
PT  - Journal Article
DEP - 20151027
PL  - New Zealand
TA  - Clin Epidemiol
JT  - Clinical epidemiology
JID - 101531700
PMC - PMC4629953
OTO - NOTNLM
OT  - comorbidity
OT  - drug-related side effects
OT  - ovarian neoplasms
OT  - platinum sensitivity
EDAT- 2015/11/26 06:00
MHDA- 2015/11/26 06:01
PMCR- 2015/10/27
CRDT- 2015/11/26 06:00
PHST- 2015/11/26 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2015/11/26 06:01 [medline]
PHST- 2015/10/27 00:00 [pmc-release]
AID - clep-7-431 [pii]
AID - 10.2147/CLEP.S86429 [doi]
PST - epublish
SO  - Clin Epidemiol. 2015 Oct 27;7:431-40. doi: 10.2147/CLEP.S86429. eCollection 2015.